The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.

Participation in the study will last about 80 weeks.

Inclusion Criteria:

• Are on stable incretin therapy at screening

• With persistent obesity or overweight defined as:

  • ≥30 kg/m2 OR

  • ≥27 kg/m2 with at least one existing obesity related complication at screening:

    • hypertension
    • dyslipidemia
    • obstructive sleep apnea
    • cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
    • type 2 diabetes

• Have a stable body weight (<5% body weight change) at screening

Exclusion Criteria:

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)

• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)

• Have type 1 diabetes

• Have taken any of the following antihyperglycemic medications within 90 days before screening:

  • dipeptidyl peptidase-4 (DPP-4) inhibitors
  • amylin analogs
  • insulin

• Have had within 90 days prior to screening:

  • heart attack
  • stroke
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure

• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.